CStone Pharmaceuticals
Edit

CStone Pharmaceuticals

http://www.cstonepharma.com/
Last activity: 27.03.2024
Categories: ResearchMedTechManagementInterestHealthTechDrugDevelopmentBusinessBioTech
CStone Pharmaceuticals (HKEX:2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
Mentions
67
Location: China, Shanghai
Employees: 201-500
Total raised: $564M
Founded date: 2016
Facebook
LinkedIn
Email

Investors 3

Funding Rounds 2

DateSeriesAmountInvestors
27.02.2019IPO$304M-
09.05.2018Series B$260M-

Mentions in press and media 67

DateTitleDescriptionSource
27.03.2024CStone Pharmaceuticals Reports 2023 Annual Results and Busin...Total revenue for 2023 was RMB463.8 million, with commercial revenue of RMB 368.1 million Healthy fi...en.prnasia...
15.03.2024CStone Announces the Fifth Indication Approved for Sugemalim...Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastri...en.prnasia...
21.12.2023CStone sells to Servier its exclusive rights to TIBSOVO® in ...The deal enables CStone to prioritize its resources to focus on the development of first-in-class an...en.prnasia...
08.12.2023CStone Announces NMPA Approval of Sugemalimab as First-line ...Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with...en.prnasia...
01.11.2023CStone Announces Strategic Partnership and Exclusive Licensi...CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commerc...en.prnasia...
31.10.2023CStone Announces NMPA Approval of Sugemalimab for Patients w...Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refrac...en.prnasia...
15.08.2023CStone Pharmaceuticals Reports 2023 Interim Results and Upda...The total revenue was RMB 261.5 million for the six months ended June 30, 2023. The sales of pharmac...en.prnasia...
27.06.2023CStone announces GAVRETO® (pralsetinib) sNDA approval by Chi...The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer marks th...en.prnasia...
15.03.2023CStone Pharmaceuticals Reports 2022 Annual Results and Busin...The total revenue for 2022 was RMB 481.4 million, with commercial revenue of RMB 394.1 million, whic...en.prnasia...
28.02.2023CStone announces China's NMPA has accepted the supplementary...This supplementary new drug application was filed for the fourth indication for sugemalimab in China...en.prnasia...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In